日本の神経バイオマーカー市場レポート：タイプ、用途、最終用途、地域別、2025年～2033年

日本の神経バイオマーカー市場規模は2024年に5億9,140万米ドルに達しました。今後、IMARC Groupは、市場は2033年までに9億5,530万米ドルに達し、2025年から2033年にかけて5.50%の成長率（CAGR）を示すと予測しています。効果的な治療プランの採用の高まりと、より迅速な医薬品開発への需要の高まりが、主に市場開発の原動力となっています。

本レポートで扱う主な質問

• 日本の神経バイオマーカー市場はこれまでどのように推移し、今後どのように推移するのか？
• COVID-19が日本の神経バイオマーカー市場に与えた影響は？
• 日本の神経バイオマーカー市場のタイプ別区分は？
• 日本の神経バイオマーカー市場の用途別区分は？
• 日本の神経バイオマーカー市場のエンドユーザー別区分は？
• 日本の神経バイオマーカー市場のバリューチェーンにおける様々なステージとは？
• 日本の神経バイオマーカーの主要な促進要因と課題は何か？
• 日本の神経バイオマーカー市場の構造と主要企業は？
• 日本の神経バイオマーカー市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 日本の神経バイオマーカー市場-イントロダクション

• 概要
• 市場力学
• 業界動向
• 競合情報

第5章 日本の神経バイオマーカー市場情勢

• 過去および現在の市場動向（2019～2024年）
• 市場予測（2025～2033年）

第6章 日本の神経バイオマーカー市場- タイプ別の内訳

• ゲノムバイオマーカー
• プロテオームバイオマーカー
• メタボロミクスバイオマーカー
• イメージングバイオマーカー
• その他

第7章 日本の神経バイオマーカー市場- 用途別の内訳

• アルツハイマー病
• パーキンソン病
• 多発性硬化症
• 自閉症スペクトラム障害
• その他

第8章 日本の神経バイオマーカー市場- 最終用途別内訳

• 病院の検査室
• 臨床診断センター
• 調査機関
• その他

第9章 日本の神経バイオマーカー市場-競合情勢

• 概要
• 市場構造
• 市場企業のポジショニング
• 主要成功戦略
• 競合ダッシュボード
• 企業評価象限

第10章 主要企業のプロファイル

第11章 日本の神経バイオマーカー市場- 業界分析

• 促進要因・抑制要因・機会
• ポーターのファイブフォース分析
• バリューチェーン分析

第12章 付録

Japan neurological biomarkers market size reached USD 591.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 955.3 Million by 2033, exhibiting a growth rate (CAGR) of 5.50% during 2025-2033. The inflating adoption of effective treatment plans and the escalating demand for faster drug development are primarily driving the market growth.

Neurological biomarkers, found in either the blood or cerebral spinal fluid (CSF), serve to facilitate the identification of brain disorders and track the advancement of diseases. These biomarkers primarily originate from genetic mutations, levels of metabolites, brain imaging, and alterations in the expression of proteins or modifications after translation. With their ability to identify biological reactions to experimental medications and assist in the exploration of novel targets for therapeutic intervention, neurological biomarkers play a significant role in clinical applications throughout the drug development process. Currently, scientists analyze the concentrations of these biomarkers to enable non-invasive testing, early diagnosis, and the customization of treatments.

Japan Neurological Biomarkers Market Trends:

The Japan neurological biomarkers market is witnessing a notable upsurge owing to the escalating prevalence of neurological disorders, including conditions like stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). This surge in neurological disorders has generated a pressing demand for accelerated drug development, thereby driving the market growth. Besides this, biomarkers play a pivotal role in measuring the effectiveness of novel medications and therapeutic approaches, contributing significantly to this momentum. Additionally, the growing acceptance of minimally invasive procedures and personalized medicine practices is serving as another crucial catalyst for market expansion in the region. Furthermore, as various neurological disorders often exhibit shared characteristics, there is an increasing requirement for multiple biomarkers to differentiate between specific diseases and their subtypes, further fueling market demand. Apart from this, advancements in mass spectrometry and imaging techniques have facilitated the rapid evaluation of numerous biochemical markers and structural changes within the brain, enabling enhanced diagnostic capabilities. This, coupled with the introduction of digital biomarkers and the continual rise in the number of clinical trials, is expected to further propel the growth of the Japan neurological biomarkers market in the forthcoming years.

Japan Neurological Biomarkers Market Segmentation:

Type Insights:

• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers
• Imaging Biomarkers
• Others

Application Insights:

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorders
• Others

End Use Insights:

• Hospital Laboratories
• Clinical Diagnostic Centers
• Research Organizations
• Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan neurological biomarkers market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan neurological biomarkers market?
• What is the breakup of the Japan neurological biomarkers market on the basis of type?
• What is the breakup of the Japan neurological biomarkers market on the basis of application?
• What is the breakup of the Japan neurological biomarkers market on the basis of end use?
• What are the various stages in the value chain of the Japan neurological biomarkers market?
• What are the key driving factors and challenges in the Japan neurological biomarkers?
• What is the structure of the Japan neurological biomarkers market and who are the key players?
• What is the degree of competition in the Japan neurological biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Neurological Biomarkers Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Neurological Biomarkers Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Neurological Biomarkers Market - Breakup by Type

• 6.1 Genomic Biomarkers
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Proteomic Biomarkers
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)
• 6.3 Metabolomic Biomarkers
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2019-2024)
  • 6.3.3 Market Forecast (2025-2033)
• 6.4 Imaging Biomarkers
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2019-2024)
  • 6.4.3 Market Forecast (2025-2033)
• 6.5 Others
  • 6.5.1 Historical and Current Market Trends (2019-2024)
  • 6.5.2 Market Forecast (2025-2033)

7 Japan Neurological Biomarkers Market - Breakup by Application

• 7.1 Alzheimer's Disease
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Parkinson's Disease
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Multiple Sclerosis
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)
• 7.4 Autism Spectrum Disorders
  • 7.4.1 Overview
  • 7.4.2 Historical and Current Market Trends (2019-2024)
  • 7.4.3 Market Forecast (2025-2033)
• 7.5 Others
  • 7.5.1 Historical and Current Market Trends (2019-2024)
  • 7.5.2 Market Forecast (2025-2033)

8 Japan Neurological Biomarkers Market - Breakup by End Use

• 8.1 Hospital Laboratories
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2019-2024)
  • 8.1.3 Market Forecast (2025-2033)
• 8.2 Clinical Diagnostic Centers
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2019-2024)
  • 8.2.3 Market Forecast (2025-2033)
• 8.3 Research Organizations
  • 8.3.1 Overview
  • 8.3.2 Historical and Current Market Trends (2019-2024)
  • 8.3.3 Market Forecast (2025-2033)
• 8.4 Others
  • 8.4.1 Historical and Current Market Trends (2019-2024)
  • 8.4.2 Market Forecast (2025-2033)

9 Japan Neurological Biomarkers Market - Competitive Landscape

• 9.1 Overview
• 9.2 Market Structure
• 9.3 Market Player Positioning
• 9.4 Top Winning Strategies
• 9.5 Competitive Dashboard
• 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

• 10.1 Company A
  • 10.1.1 Business Overview
  • 10.1.2 Services Offered
  • 10.1.3 Business Strategies
  • 10.1.4 SWOT Analysis
  • 10.1.5 Major News and Events
• 10.2 Company B
  • 10.2.1 Business Overview
  • 10.2.2 Services Offered
  • 10.2.3 Business Strategies
  • 10.2.4 SWOT Analysis
  • 10.2.5 Major News and Events
• 10.3 Company C
  • 10.3.1 Business Overview
  • 10.3.2 Services Offered
  • 10.3.3 Business Strategies
  • 10.3.4 SWOT Analysis
  • 10.3.5 Major News and Events
• 10.4 Company D
  • 10.4.1 Business Overview
  • 10.4.2 Services Offered
  • 10.4.3 Business Strategies
  • 10.4.4 SWOT Analysis
  • 10.4.5 Major News and Events
• 10.5 Company E
  • 10.5.1 Business Overview
  • 10.5.2 Services Offered
  • 10.5.3 Business Strategies
  • 10.5.4 SWOT Analysis
  • 10.5.5 Major News and Events

11 Japan Neurological Biomarkers Market - Industry Analysis

• 11.1 Drivers, Restraints, and Opportunities
  • 11.1.1 Overview
  • 11.1.2 Drivers
  • 11.1.3 Restraints
  • 11.1.4 Opportunities
• 11.2 Porters Five Forces Analysis
  • 11.2.1 Overview
  • 11.2.2 Bargaining Power of Buyers
  • 11.2.3 Bargaining Power of Suppliers
  • 11.2.4 Degree of Competition
  • 11.2.5 Threat of New Entrants
  • 11.2.6 Threat of Substitutes
• 11.3 Value Chain Analysis

12 Appendix